Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ForwardVue Pharma has secured initial seed round funding in order to advance pre-clinical development of potent long acting anti-angiogenic molecules directed against diabetic eye disease and neovascular age related macular degeneration.
Lead Product(s): Caroboxyamidotriazole
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding August 26, 2020